Gavin Redhead, a patient advocate, tells us how heart failure healthtech recommended by NICE helped transform his life.
Thousands of people in England with a type of chronic heart failure are eligible for a new treatment option following our final draft guidance that recommends finerenone for adults with chronic heart ...
NICE is unable to make a recommendation on lutetium-177 vipivotide tetraxetan (Pluvicto) for treating prostate-specific membrane antigen (PSMA)-positive hormone-relapsed metastatic prostate cancer in ...
Independent committees develop our recommendations. NICE committees are made up of people like you. They include experts in health and social care, people who use health and care services and carers.
There are different ways to get involved in NICE’s work and help us to improve NHS and care services for other people – either those who are like you, or those communities you represent as part of a ...
There is a simple discount patient access scheme for teplizumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact GB-PatientAccess ...
There is a simple discount patient access scheme for pirtobrutinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
There is a simple discount patient access scheme for cemiplimab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results